Cost of cancer care: Issues and implications

Journal of Clinical Oncology

Volumn 25, Issue 2, 2007, Pages 180-186

  Meropol, Neal J ^a   Schulman, Kevin A ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; INFLIXIMAB; IRINOTECAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OXALIPLATIN; PANITUMUMAB; PARICALCITOL; PNEUMOCOCCUS VACCINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; ZOLEDRONIC ACID;

ADJUVANT THERAPY; CANCER CENTER; CANCER DIAGNOSIS; CANCER THERAPY; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFICACY; FOLLOW UP; HEALTH BEHAVIOR; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LIFE EXPECTANCY; MEDICAL TECHNOLOGY; MONOTHERAPY; ONCOLOGY; PRIORITY JOURNAL; PROSPECTIVE PRICING; REVIEW; ECONOMICS; HEALTH ECONOMICS; NEOPLASM; UNITED STATES;

BIOMEDICAL TECHNOLOGY; ECONOMICS, MEDICAL; HEALTH CARE COSTS; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; MEDICAL ONCOLOGY; NEOPLASMS; UNITED STATES;

EID: 33846974021     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.09.6081     Document Type: Review

References (72)

1. Borger C, Smith S, Truffer C, et al: Health spending projections through 2015: Changes on the horizon. Health Aff (Millwood) 25:w61-w73, 2006
2. Heffler S, Smith S, Keehan S, et al: Trends: U.S. health spending projections for 2004-2014. Health Aff (Millwood) Suppl Web Exclusives 24:W5-74-W75-85, 2005
3. World Health Organization: WHOSIS (WHO Statistical Information System): A guide to statistical information at WHO - World health statistics 2006. http://www.who.int/whosis/en/
4. Bodenheimer T: High and rising health care costs: Part 1. Seeking an explanation. Ann Intern Med 142:847-854, 2005
5. American Cancer Society: Cancer facts and figures 2006, 2006 update. http://www.cancer.org/ downloads/STT/CAFF2006PWSecured.pdf
6. U.S. Census Bureau: U.S. Interim Projections by age, sex, race, and Hispanic origin, 3/04 update. http://www.census.gov/ipc/www/usinterimproj/
7. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
8. Ginsburg GS, Konstance RP, Allsbrook JS, et al: Implications of pharmacogenomics for drug development and clinical practice. Arch Intern Med 165:2331-2336, 2005
9. Report to Congress: Variation and innovation in medicare, 6/06 update. www.medpac.gov/publications/ congressional_reports/June03_Ch9.pdf
10. Federal Drug Administration: Innovation or stagnation: Challenge and opportunity on the critical path to new medical products, 3/04 update. http://www .fda.gov/oc/initiatives/criticalpath/whitepaper.pdf
11. Hoffman JM, Shah ND, Vermeulen LC, et al: Projecting future drug expenditures: 2006. Am J Health Syst Pharm 63:123-138, 2006
12. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55:10-30, 2005
13. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047, 2000
14. Hoff PM, Ansari R, Batist G, et al: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 19:2282-2292, 2001
15. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer: Irinotecan Study Group. N Engl J Med 343:905-914, 2000
16. Van Cutsem E, Twelves C, Cassidy J, et al: Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 19:4097-4106, 2001
17. Grothey A, Sargent D, Goldberg RM, et al: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracilleucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22:1209-1214, 2004
18. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
19. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
20. Peeters M, Van Cutsem E, Siena S, et al: A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) versus BSC alone in patients with metastatic colorectal cancer. Proc Am Assoc Cancer Res 47:408, 2006 (abstr)
21. Wong Y, Meropol NJ, Sargent D, et al: Direct cost-survival analysis of therapies for metastatic colorectal cancer. J Clin Oncol 24:149s, 2006 (suppl; abstr 3515)
22. Siu AL, Sonnenberg FA, Manning WG, et al: Inappropriate use of hospitals in a randomized trial of health insurance plans. N Engl J Med 315:1259-1266, 1986
23. Gabel J, Claxton G, Holve E, et al: Health benefits in 2003: Premiums reach thirteen-year high as employers adopt new forms of cost sharing. Health Aff (Millwood) 22:117-126, 2003
24. Huskamp HA, Deverka PA, Epstein AM, et al: The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med 349:2224-2232, 2003
25. Curtis LH, Law AW, Anstrom KJ, et al: The insurance effect on prescription drug expenditures among the elderly: Findings from the 1997 Medical Expenditure Panel Survey. Med Care 42:439-446, 2004
26. Arrow KJ: Uncertainty and the welfare economics of medical care. J Health Polit Policy Law 26:851-883, 1963
27. Arrow KJ: The economics of moral hazard: Further comment. Am Econ Rev 58 537-539, 1968
28. Friedman M: How to cure health care. Public Interest 142:3-30, 2001
29. Pauly MV: The economics of moral hazard: Comment. Am Econ Rev 58:531-537, 1968
30. Schrag D: The price tag on progress: Chemotherapy for colorectal cancer. N Engl J Med 351:317-319, 2004
31. Jacobson M, O'Malley AJ, Earle CC, et al: Does reimbursement influence chemotherapy treatment for cancer patients? Health Aff (Millwood) 25:437-443, 2006
32. Miller DC, Gruber SB, Hollenbeck BK, et al: Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98:1134-1141, 2006
33. Iglehart JK: The new era of medical imaging: Progress and pitfalls. N Engl J Med 354:2822-2828, 2006
34. Kahneman D, Tversky A: Prospect theory: An analysis of decisions under risk. Econometrica 47: 263-291, 1979
35. Gaskin DJ, Weinfurt KP, Castel LD, et al: An exploration of relative health stock in advanced cancer patients. Med Decis Making 24:614-624, 2004
36. Gaskin DJ, Kong J, Meropol NJ, et al: Treatment choices by seriously ill patients: The Health Stock Risk Adjustment model. Med Decis Making 18:84-94, 1998
37. Rasiel EB, Weinfurt KP, Schulman KA: Can prospect theory explain risk-seeking behavior by terminally ill patients? Med Decis Making 25:609-613, 2005
38. Ellis M: GM health-care costs rise despite Medicare change. Reuters, March 11, 2004 update. http://www.forbes.com/business/newswire/2004/ 03/11/rtr1295576.htlm
39. United Auto Workers Ford Report: Voluntary system-wide buyouts offer for UAW Ford workers, 9/06 update. www.uaw.org/news/091406volunar buyouts.pdf
40. Pauly MV: Should we be worried about high real medical spending growth in the United States? Health Aff (Millwood) 22:W3-15-W3-27, 2003
41. Chernew M, Cutler DM, Keenan PS: Increasing health insurance costs and the decline in insurance coverage. Health Serv Res 40:1021-1039, 2005
42. Institute of Medicine: Care Without Coverage: Too Little Too Late. Washington, DC, National Academies Press, 2002
43. Hadley J: Sicker and poorer - The consequences of being uninsured: A review of the research on the relationship between health insurance, medical care use, health, work, and income. Med Care Res Rev 60:3S-75S, 2003 (suppl 2)
44. Strunk BC, Cunningham PJ: Treading water: Americans' access to needed medical care, 1997-2001. Track Rep 1-6, 2002
45. Arnst C: Going broke to stay alive. Business Week 36-38, 2006
46. Berenson A: A cancer drug's big price rise disturbs doctors and patients. New York Times March 12, 2006:A1
47. Berenson A. A cancer drug shows promise, at a price that many can't pay. New York Times February 15, 2006:A1
48. MedPAC: Payment basics: Part D payment system. http://www.medpac.gov/ publications/other _reports/Sept06_MedPAC_Payment_Basics_PartD.pdf
49. Laetz T, Silberman G: Reimbursement policies constrain the practice of oncology. JAMA 266: 2996-2999, 1991
50. Compilation of the Social Security Laws: Exclusions from coverage and medicare as secondary payer, 6/2006 update. http://www.ssa.gov/ OP_Home/ssact/title18/1862.htm
51. Tunis SR: Why Medicare has not established criteria for coverage decisions. N Engl J Med 350: 2196-2198, 2004
52. Adams CP, Brantner VV: Estimating the cost of new drug development: Is it really 802 million dollars? Health Aff (Millwood) 25:420-428, 2006
53. DiMasi JA, Grabowski HG: The economics of new oncology drug development. J Clin Oncol 25: 209-216, 2007
54. Meropol NJ, Desmond-Hellmannn S, Tunis S, et al: Can society afford state-of-the-art cancer treatment? Am Soc Clin Oncol Ed Book 473-480, 2005
55. Drummond MF, Mason AR: Costs and costeffectiveness of cancer therapies: A European perspective. J Clin Oncol 25:191-195, 2007
56. Ridley DB, Schulman KA: Differential pricing of pharmaceuticals in the Internet age. J Ambul Care Manage 27:210-214, 2004
57. Ward E, Jemal A, Cokkinides V, et al: Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54:78-93, 2004
58. Bickell NA, Wang JJ, Oluwole S, et al: Missed opportunities: Racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24:1357-1362, 2006
59. Edwards BK, Brown ML, Wingo PA, et al: Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97:1407-1427, 2005
60. Meissner HI, Breen N, Klabunde CN, et al: Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev 15:389-394, 2006
61. Bach PB, Cramer LD, Warren JL, et al: Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341:1198-1205, 1999
62. Institute of Medicine: Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare. Washington, DC, National Academies Press, 2002
63. Income, poverty, and health insurance coverage in the United States: 2005, update. http://www .census.gov/prod/2006pubs/p60-231.pdf
64. Bach P: Cost of cancer care: A view from the Centers for Medicare & Medicaid Services. J Clin Oncol 25:187-190, 2007
65. Knudsen AB, McMahon P, Gazelle GS: Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol 25:203-208, 2007
66. Grusenmeyer P, Wong Y: Using cost effectiveness analysis to improve cancer care. J Clin Oncol 25:196-202, 2007
67. Kim P: Cost of cancer care: The patient perspective. J Clin Oncol 25:228-232, 2007
68. Pauly M: Is high and growing spending on cancer treatment and prevention harmful to the U.S. economy? J Clin Oncol 25:171-174, 2007
69. Ramsey S: How should we pay the piper when he's calling the tune? On the long term affordability of cancer care in the United States. J Clin Oncol 25:175-179, 2007
70. Schrag D: Provider perspectives. J Clin Oncol 25:10.1200/JCO.2006
71. Sulmasy DP: Cancer care, money, and the value of life: Whose justice? Which rationality? J Clin Oncol 25:217-222, 2007
72. Weinfurt KP: Challenges for assessing the value of high-cost cancer care: A behavioral science perspective. J Clin Oncol 25:223-227, 2007